Silver coatings to combat catheter associated infections

银涂层可对抗导管相关感染

• 批准号: 7049688
• 负责人: BRUCE L GIBBINS
• 金额: $ 14.37万
• 依托单位: ACRYMED, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-01 至 2006-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7049688
• 关键词: antiinfective agents; biofilm; biomaterial compatibility; biomaterial development /preparation; biomedical equipment development; cell mediated lymphocytolysis test; cell proliferation; chemical synthesis; disease /therapy duration; fibroblasts; growth inhibitors; human tissue; keratinocyte; nosocomial infection control; polymers; silicon compounds; silver; slow release drug; surface coating; tissue /cell culture; urinary catheterization

DESCRIPTION (provided by applicant): Abstract Indwelling catheterization is a leading cause of nosocomial infections that present an enormous drain of health care funding in the US. Clinical infections associated with urinary catheterization have been estimated to add more than $1000 to patient care. Those that occur with central venous catheterization escalate the cost to between $35,000 and $50,000 per infection, with a mortality rate that exceeds 35%. The incorporation of antimicrobiotics and antiseptics into catheter materials in order to reduce the rate of associated infections has been investigated for the past thirty years with limited success. In particular, it has been difficult to demonstrate that antimicrobial catheters provide a significant clinical benefit when used for long-term catheterization (> 1 week). The main limitation has been to obtain a sufficient sustained release of the antimicrobial agent to prevent the colonization and biofilm formation that serves as a reservoir for infecting microbes. We have developed a stabilized sustained release silver reservoir that has proven to be highly effective in prolonging the antimicrobial activity in a number of wound care products. Preliminary studies have shown that this technology is adaptable for use in hydrophobic silicone materials, and treated catheters can inhibit microbial growth and biofilm formation for at least 10 days. This project is intended to confirm and extend our initial observations with the aim of perfecting a technology for improving catheters. Successful commercialization would significantly improve catheter design and contribute to a reduction in health care expenditure for nosocomial infections.

描述（由申请人提供）：抽象的留置导管插入术是医院感染的主要原因，在美国散发出大量的医疗保健资金。据估计，与尿导管插入术有关的临床感染估计为患者护理增加了1000多美元。那些发生中央静脉导管插入术的人将成本升至每次感染35,000至50,000美元之间，死亡率超过35％。在过去的30年中，已经研究了将抗菌和抗菌素掺入导管材料中，以降低相关感染的速度，成功的成功有限。特别是，很难证明抗菌导管在用于长期导管插入术（> 1周）时为临床益处提供了重大临床益处。主要局限性是获得足够的持续释放抗微生物剂，以防止作为感染微生物的储层的定殖和生物膜形成。我们已经开发了稳定的持续释放的银储液，该储层被证明在延长许多伤口护理产品中的抗菌活性方面非常有效。初步研究表明，该技术可用于疏水硅材料，并且经过处理的导管可以抑制微生物生长和生物膜形成至少10天。该项目旨在确认和扩展我们的最初观察结果，以完善改善导管的技术。成功的商业化将显着改善导管设计，并有助于减少医疗医疗感染的医疗支出。